Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MESO)

Mesoblast's Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion

GlobeNewswire December 17, 2019

Mesoblast Finanical Results for the Quarter Ended September 30, 2019

GlobeNewswire November 25, 2019

Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019

GlobeNewswire November 21, 2019

Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast's Potential First United States Allogeneic Cell Therapy

GlobeNewswire October 16, 2019

Mesoblast Completes Successful Institutional Capital Raising of A$75 Million

GlobeNewswire October 3, 2019

Mesoblast Corporate Update: Analyst Call

GlobeNewswire September 9, 2019

Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

GlobeNewswire September 9, 2019

Mesoblast Reports 2019 Full Year Results

GlobeNewswire August 29, 2019

Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019

GlobeNewswire August 27, 2019

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD

GlobeNewswire August 27, 2019

Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial

GlobeNewswire August 14, 2019

Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer

GlobeNewswire August 12, 2019

Mesoblast Quarterly Cash Flow Report

GlobeNewswire July 31, 2019

Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure

GlobeNewswire July 25, 2019

Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices

GlobeNewswire June 24, 2019

High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease

GlobeNewswire June 18, 2019

UPDATE - Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease

GlobeNewswire June 14, 2019

Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease

GlobeNewswire June 14, 2019

Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain

GlobeNewswire June 11, 2019

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019

GlobeNewswire May 30, 2019